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Abstract 34 
CML presenting with a variant Philadelphia translocation, atypical BCR-ABL transcript, 35 
additional chromosomal aberrations and evolving MDS is uncommon and therapeutically 36 
challenging. The prognostic significance of these genetic findings is uncertain even as singular 37 
aberrations, with nearly no data on management and outcome when they coexist. MDS 38 
evolving during the course of CML may be either treatment-associated or an independently 39 
coexisting disease, and is generally considered to have an inferior prognosis. Tyrosine kinase 40 
inhibitors (TKI) directed against BCR-ABL are the mainstay of treatment for CML, whereas 41 
treatment modalities that may be utilized for both MDS and CML include allogeneic stem cell 42 
transplant and – at least conceptually – hypomethylating agents.  Here, we describe the clinical 43 
course of such a patient, demonstrating that long-term combined treatment with dasatinib and 44 
azacitidine for coexisting CML and MDS is feasible and well tolerated, and may be capable of 45 
slowing disease progression. This combination therapy had no deleterious effect on 46 
subsequent potentially curative haploidentical bone marrow transplantation. The different 47 
prognostic implications of this unusual case and new therapeutic options in CML are discussed, 48 
together with a review of the current literature on CML presenting with different types of 49 
genomic aberrations and the coincident development of MDS. 50 
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Introduction 62 
Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder that is driven by 63 
the BCR-ABL1 oncogene. The reciprocal BCR-ABL1 translocation involves chromosomes 22 64 
and 9 and leads to a fusion gene that encodes a constitutively active oncogenic kinase, 65 
typically referred to as p210BCR-ABL1. Details of the molecular pathogenesis of CML have been 66 
described in numerous seminal papers and excellent reviews [1]–[4]. Tyrosine kinase inhibitors 67 
(TKI) that inhibit BCR/ABL1 signaling have become the gold standard of CML treatment, with 68 
five TKIs presently approved for clinical use: imatinib was followed by dasatinib, nilotinib and 69 
bosutinib as second generation TKIs and ponatinib as third generation TKI. Together with 70 
rigorous cytogenetic and molecular monitoring of treatment response, this armamentarium has 71 
transformed CML from a mostly fatal leukemia to a disease with an excellent prognosis in the 72 
vast majority of patients, the goal of a normal life expectancy and even prospect for cure in a 73 
subset of patients. The nearly invariable transition from an initial chronic phase to accelerated 74 
and ultimately blast phase in the pre-TKI era has become exceedingly rare [5]. Importantly, 75 
the prognosis of patients that do experience such progression remains very poor despite all 76 
currently available treatment options. Consequently, patients destined to do poorly should be 77 
identified at an early stage. This relies on two complementary strategies, i.e. i) evaluation of 78 
the prognosis at diagnosis using a variety of scoring systems, such as the EUTOS, Sokal or 79 
Hasford scores [6]–[8] and ii) assessment of the speed of hematologic, cytogenetic and 80 
molecular responses during first-line or second-line therapy. The European Leukemia Net 81 
(ELN) provides distinct recommendations for CML treatment based on classification of a 82 
patient`s response as optimal or failure [9]–[11]. Additional warning signs that warrant close 83 
supervision, but for which no unequivocal treatment guidelines have been defined include 84 
additional chromosomal aberrations (ACAs), either in the Ph positive clone or in Ph negative 85 
cells as evidence of clonal evolution, and atypical BCR-ABL1 transcripts. These aberrations, 86 
which may be identified at diagnosis or during therapy have been variably associated with an 87 
inferior or uncertain prognosis. By themselves none of these findings are considered an 88 
unequivocal trigger for changing therapy, although cytogenetic findings consistent with the 89 
presence or development of a myelodysplastic syndrome, e.g. monosomy 5 or monosomy 7, 90 
are considered ominous signs.  91 
Myelodysplastic syndromes (MDS) are a group of diseases of the hematopoietic stem cell 92 
characterized by peripheral cytopenias that variably effect erythro-, thrombo- and 93 
granulopoiesis and an increasing proportion of BM blasts. As in CML, prognosis and treatment 94 
are based on several clinical scoring systems. Treatment of MDS is stage-dependent and 95 
includes supportive care (transfusions and antibiotic prophylaxis), disease-modifying 96 
hypomethylating agents (azacitidine and/or decitabine) to stabilize the course of the disorder 97 
and delay acceleration into an acute myelogenous leukemia [12]–[14] or allogeneic stem cell 98 
transplantation in the small subset of patients deemed fit enough to undergo this procedure. 99 
In rare cases, MDS develops during treatment for CML [15]; no standard therapy has to date 100 
been established for patients in whom both diseases coexistent.  101 
In this report we describe the case of a 41 years old female diagnosed with CML, whose clinical 102 
course was characterized by several of the above mentioned features: an atypical transcript, 103 
ACAs and an evolving MDS (see Tab.1).  104 
 105 
Case report 106 
A 41 years old female presented in 01/2001 with bone pain, leuko- and thrombocytosis. Her 107 
WBC was 19.000/µl, ANC: 14.000/µl, Hb: 13.4 g/dl and platelets: 517.000/mm³ (see Fig.1A-108 
C). Cytogenetic analysis revealed a variant BCR-ABL1 translocation 109 
(46,XX,t(9;22;17)(q34;q11;q24)) (9 of 9 metaphases) (see Tab.2). Molecular genetic analysis 110 
by direct sequencing identified an atypical BCR-ABL1 transcript (p190Bcr-Abl (b2a3)), also 111 
referred to as (p190Bcr-Abl (e1a3)) according to revised nomenclature[16]. A diagnosis of Ph+ 112 
CML in chronic phase was established. Treatment with hydroxyurea was initiated in 02/2001. 113 
This resulted in control of WBC but no molecular response. Interferon-α was contraindicated 114 
due to clinical depression. Two years and 3 months after diagnosis (05/2003), imatinib was 115 
started at an initial dose of 400mg/day. Peripheral edema necessitated dose reduction to 300 116 
mg/day. The BCR-ABL1/ABL1 ratio decreased to 18% after one year (04/2004) (detected with 117 
a p210-transcript assay via RT-PCR, with G6PD as housekeeping gene) and imatinib was 118 
continued at 300mg/day. After 2 more years a non-variant translocation (46,XX,t(9;22)[19/25]) 119 
was observed by cytogenetic analysis, accompanied by an increasing BCR-ABL1/ABL1 ratio 120 
(62% detected with an p210 transcript assay via RT-PCR). The imatinib dose was increased 121 
to 300/400mg alternating per day (see also Fig.2). Neither the variant translocation nor the 122 
atypical BCR-ABL1 transcript were detectable at that time using a p210 RT-PCR assay and 123 
nested PCR approach. Despite failure of TKI treatment the patient refused an allogeneic 124 
hematopoetic stem cell transplantation (HSCT). 125 
Shortly thereafter (06/2006) hematologic CR was lost with left-shift in the peripheral blood 126 
smear and mild to moderate cytopenia (WBC 2,61/nl, ANC 0.9/nl, plts. 138/nl and Hb 12.7 g/dl; 127 
see Fig.1A-C). Cytogenetic analysis (08/2006) revealed the same variant BCR-ABL 128 
translocation that had been observed at initial diagnosis, (46,xx,t(9;22;17)[4/20]) in conjunction 129 
with a newly occurring monosomy 7 (45,XX,-7 [16/20]) (see Tab.2). At that timepoint no BCR-130 
ABL mutation was detectable in sanger sequencing. Imatinib was switched to Nilotinib 131 
400mg/BD within a clinical trial, with hematologic remission within 2 months and a complete 132 
cytogenetic remission of the Ph positive CML within 14 months but persistence of the 133 
monosomy 7 in all metaphases (45,XX,-7 [19/19]) (see also Fig.2 and Tab.2). Accordingly, 134 
monosomy 7 was present in the Ph negative clone. 135 
Cytogenetic remission with respect to the t(9;22) lasted for an additional year until cytogenetic 136 
relapse occurred in 04/2008 (46,XX,t(9;22;17)[3/21]; 45,XX,-7 [18/21]) and treatment was 137 
switched to dasatinib (50mg/day). Ph-negativity was regained within 3 months, with 138 
persistence of monosomy 7 in bone marrow cytogenetics (45,XX,-7 [20/20]) in 08/2008. 139 
This coincided with worsening of cytopenias, appearance of profoundly dysmorphic 140 
megakaryopoiesis and erythropoiesis and severely reduced granulopoiesis by bone marrow 141 
examination, without an increase of blasts; the additional diagnosis of an MDS was established 142 
(see Fig.1A-C,2). The IPSS and WPSS scores were intermediate-1 and high, respectively. 143 
Dasatinib was continued to maintain control of CML and azacitidine was added in 12/2008 at 144 
a dosage of 75mg/m2 s.c. for five consecutive days (days 1 to 5 of a 4 weekly treatment 145 
schedule, reduced dosage due to present cytopenia). Azacitidine administration was changed 146 
to i.v. infusion after severe skin irritation with s.c. administration. Combined dasatinib and 147 
azacitidine was continued for another three years with a sustained complete cytogenetic 148 
response of the Philadelphia positive clone, whereas monosomy 7 continued to be detected 149 
in 90% to 100% of metaphases on bone marrow analysis (see Tab.2). Peripheral blood counts 150 
showed transfusion independent anemia (grade 1-2), mild thrombocytopenia (grade 1-2) and 151 
grade 4 (severe) granulocytopenia (see Fig 1). 152 
Cytogenetic relapse of the CML with reappearance of the t(9;22;17) in 2 of 21 metaphases 153 
and clonal evolution with a new distinct clone with t(2;22) in 6 of 21 metaphases was observed 154 
in 05/2011(10 years after initial diagnosis and 2,5 years of combination therapy), with 155 
additionally no detectable BCR-ABL mutation upon sanger sequencing. All remaining 156 
metaphases demonstrated monosomy 7 (13 of 21 metaphases) (see Tab.2). Molecular genetic 157 
analysis revealed KRAS, ASXL1 and ETV6 mutations (see Fig.2), which by backtracking 158 
analysis of prior diagnostic bone marrow samples had not been present at initial diagnosis of 159 
CML and also not at development of myelodysplasia.  160 
In view of persisting MDS with clonal evolution and resistant CML by cytogenetics the patient 161 
agreed to undergo an allogenic HSCT. As no matched related or unrelated donor could be 162 
identified, haplo-identical bone marrow transplantation (BMT) was performed in 09/2011 with 163 
one of her daughters as stem cell donor. Dasatinib and azacitidine were discontinued prior to 164 
start of the conditioning which included thiotepa, i.v. busulfan and fludarabine. GvHD 165 
prophylaxis was conducted with posttransplant cyclophosphamide and the conitnous 166 
treatment with mycophenolate-mofetil (MMF) and cyclosporine A (CSA). The patient engrafted 167 
and haematopoesis recovered adaequately with complete donor chimerism. The BMT resulted 168 
in complete recovery of peripheral blood counts after 19 days (granulocytes >0,5/nl) resp. 30 169 
days (thrombocytes >50/nl) (see Fig.1A-C),  and complete cytogenetic and molecular 170 
remission.  171 
The patient developed a mild acute grade 1 graft versus host disease (GvHD) of the oral cavity, 172 
which was treated with prednisolone. One year after BMT she developed a steroid dependent 173 
moderate chronic GvHD.  174 
Complete cytogenetic and molecular remission persisted until 2.5 years after BMT, when 175 
atypical BCR-ABL1 transcripts were again detected by nested PCR, but a quantitative RT-176 
PCR assay could not be performed due to the atypical transcript. Cytogenetics were normal 177 
and full donor chimerism persisted in the bone marrow. Treatment of molecular relapse with 178 
nilotinib led to a disappearance of BCR-ABL1 transcript in nested PCR analysis, even though 179 
nilotinib was discontinued after 28 days because of gastrointestinal and musculoskeletal side 180 
effects and elevated liver function tests (transaminases). Except for two analyses revealing 181 
low level atypical BCR-ABL1 transcripts on day +1036 and day +1477 by nested PCR, which 182 
disappeared without treatment at both time-points, the patient has to date remained in 183 
complete cytogenetic and molecular remission with respect to both CML and MDS-associated 184 
aberrations.  185 
In summary this disease and treatment course of CML with atypical BCR-ABL1 transcript, MDS 186 
and clonal evolution demonstrates the initial coexistence of two distinct diseases with 187 
development of TKI-refractory CML in the absence of a BCR-ABL kinase domain mutation. 188 
Moreover, we to our knowledge for the first time demonstrate that long-term combined 189 
treatment with dasatinib and azacitidine is feasible and well tolerated, and may be capable of 190 
slowing disease progression. This combination may also be warranted for treatment of CML 191 
patients responding poorly to standard therapy. 192 
 193 
Review of the literature  194 
The above case provides several interesting insights into the relation of evolving cytogenetic 195 
and molecular findings during the development of CML-associated myelodysplasia, the 196 
kinetics of clonal evolution and therapeutic options in the face of TKI failure. We here review 197 
these different aspects and the current understanding of their impact on prognosis, and discuss 198 
them in context of the individual patient described above. 199 
 200 
Variant Bcr-Abl translocations and atypical transcripts 201 
Variant BCR-ABL translocations involve more or other chromosomes than chromosomes 9 202 
and 22. Their frequency in CML patients is approximately 6% [17], [18] and in the pre-imatinib 203 
era the prognosis was suggested to be inferior [2], [19], [20]. With TKI-based therapy conflicting 204 
results have been reported: an inferior prognosis was suggested by Stagno et al. based on a 205 
small cohort of 10 CML patients treated with imatinib or nilotinib as first-line therapy (7 206 
suboptimal response, one TKI failure and 2 optimal responses) [21]. In contrast El-Zimarty and 207 
Marzochchi et al. reported that response and outcome of 30 patients treated with imatinib was 208 
identical to that of 44 patients harboring the common t(9;22) translocation in terms of CCyR, 209 
MMR [18], [22]. Variant translocations have been speculated to be markers of genomic 210 
instability [20], [21] with a consequently inferior prognosis, but they do not constitute a warning 211 
sign according to ELN criteria [11] (see also Tab.1).  212 
Atypical BCR-ABL1 transcripts have different sizes and breakpoints compared to the usual 213 
p210 or p190 transcript and have been reported in approximately 1-2% of BCR-ABL1 positive 214 
ALL patients [23] and more sporadically in CML [24]–[27]. Atypical transcripts are usually 215 
noticed on polyacrylamide gel in conventional PCR because of their different size, but may be 216 
missed in some cases. Failure to identify atypical transcripts can have a negative impact on 217 
treatment outcome due to inadequate disease monitoring (see also Tab.1). As in our case, 218 
quantification in RT PCR assays can be difficult, particularly when transcript numbers are low. 219 
Therefore, qualitative detection in a nested PCR approach can be helpful. The p190Bcr-Abl b2a3 220 
(or e1a3) transcript detected in our patient has so far been reported only in rare cases of CML 221 
[28], [29] and ALL[30], [31]. It has been proposed that atypical transcripts lacking exon a2 222 
should have a more benign course of the disease [16], [28]. In line with this, several 223 
publications describe a benign course under TKI treatment in CML patients with these 224 
transcripts [32]–[36] (see also Tab.1). 225 
Contrary to these reports, our patient displayed an unfavorable course of the disease with 226 
primary resistance to imatinib, an only brief CCyR of less than a year duration on nilotinib and 227 
a temporary cytogenetic response to dasatinib, leading to the indication for allogenic SCT as 228 
discussed below. 229 
 230 
Additional chromosomal aberrations (ACAs) in Ph-positive clones 231 
Additional chromosomal aberrations (ACAs) can occur in the Ph positive and Ph-negative 232 
clones. ACAs in the Ph-positive clone occur in approximately 5% of patients overall, and 233 
increase in frequency in late chronic, accelerated and blast phase CML (30-80%) [37]. 234 
Chromosomes Y, 7, 8 or 19 are involved most frequently [37], [38]. Presence of ACAs already 235 
at diagnosis has been suggested by Luatti et al. to have a negative impact on prognosis with 236 
imatinib, based on delayed achievement of CCyR and MMR. These authors propose closer 237 
monitoring, in particular with major route chromosomal aberrations [37]. ACAs in a Ph-positive 238 
clone developing during TKI are considered hallmarks of clonal evolution, and are variably 239 
associated with imatinib-resistance [38]. While some studies showed no adverse impact of 240 
ACAs on the probability of achieving a MMR, other reports have linked ACAs with an adverse 241 
prognosis with TKI treatment (imatinib) [39]–[41] as well as in the pre-TKI era [42]. Despite the 242 
uncertain clinical relevance of ACAs representing clonal evolution, current ELN guidelines 243 
consider ACAs as a „warning sign“ [11].  244 
 245 
Additional chromosomal aberrations (ACAs) in Ph-negative clones 246 
The appearance of ACAs in Ph-negative cells is a rare occurrence, has been observed under 247 
treatment with interferon-α and imatinib [43], and most frequently involves chromosomes 8,7 248 
and Y. Unmasking of preexisting ACAs by treatment appears to be the most common cause 249 
[44], but the possibility that imatinib itself could induce ACAs by impairing DNA damage repair 250 
has been raised in several preclinical reports [45]–[47]. The overall role of imatinib in promoting 251 
ACA development remains unclear, however [44]. The clinical relevance of ACAs in a Ph-252 
negative clone is also uncertain. Most ACAs are typical of those seen in AML and MDS, but 253 
very few CML patients with ACAs actually developed clinically overt MDS (11%) and 254 
progression to AML appears to be even less frequent [43], [48], [49]. The clinical course 255 
following emergence of ACAs is highly variable: Some studies report an incidence of ACAs of 256 
3.4% to 8.7% under imatinib treatment, a median time to appearance of 13.3 months and no 257 
association with MDS or CML progression [48], [50], [51] or a negative impact on outcome [17], 258 
[52] and in some cases even an only transient appearance is described [50]. The presence of 259 
ACAs in Ph-negative seem to have no impact on the median time to CCyR with imatinib-260 
treatment, or on overall and progression free survival [52] (see Tab.1). 261 
In monosomy 7 in particular, results are variable: Kovitz et al. identified 17 patients treated with 262 
imatinib who developed MDS or AML. Ten of these patients had chromosome 7 abnormalities, 263 
in 5 cases a monosomy 7, suggesting that monosomy 7 denotes a higher probability for 264 
appearance of an MDS [53].  Other published reports on small series of MDS cases coinciding 265 
with ACAs suggest a poor prognosis of patients with monosomy 7 [53], [54]. In 2011 Groves 266 
et al. reported that patients with monosomy 7 or del(7q) in Ph neg. clones in CML have a 267 
significant risk of a second myeloid malignancy, with 15 of 50 patients developing MDS or AML 268 
within 6 months of ACA detection [55]. However, benign disease course has also been 269 
described [56], without the appearance of MDS despite of the presence of monosomy 7 [48], 270 
[50], [51]. 271 
In summary, detection of ACAs warrants continued cytogenetic analyses rather than reliance 272 
on monitoring only of BCR-ABL1 transcripts. Any therapeutic interventions have to be 273 
considered on the basis of the individual ACA. For example, appearance of monosomy 7 alone, 274 
without clinical signs of myelodysplasia is a warning sign but does not constitute an indication 275 
for MDS-directed therapy [52]. These patients should be monitored closely in order not to miss 276 
development of MDS, but for individual patients, clinical decisions need to consider the 277 
considerable heterogeneity in outcome among patients with monosomy 7 and dysplasia, as 278 
both benign courses as well as rapid progression to AML have been described. Further studies 279 
are needed to elucidate the reasons underlying the variable prognosis of CML patients with 280 
ACAs and myelodysplasia. 281 
 282 
Myelodysplasia in CML 283 
Myelodysplasia in CML patients can been observed as TKI-related side effect and as a 284 
development of an MDS/MPN overlap syndrome [57]. An MDS may be suspected in case of 285 
unexplained cytopenia, which must be distinguished from the initial and usually transient 286 
cytopenia that may occur during the early period of TKI therapy, which if prolonged is an 287 
adverse risk feature in CP-CML, and from the cytopenias associated with accelerated phase 288 
CML [15]. The frequency of severe neutro- and thrombopenias and anemia are reported in a 289 
range of 4%-21%, 2%-12% thrombopenia and 0%-10%, respectively and are comparable with 290 
nilotinib and dasatinib treatment [58]. Overall, MDS is a rare cause of cytopenia in patients 291 
with CML [15], [53]; a causal relationship with TKI treatment has been postulated partly 292 
because MDS has not been observed during interferon-alpha treatment [59]. Coexistence of 293 
dysplasia and myeloproliferative features resembling an MPN/MDS overlap syndrome 294 
constitutes a specific entity classified as atypical CML/MDS [60]. It is defined as a BCR-ABL1 295 
negative disease with less than 20% blasts in the bone marrow and hypercellular granulocytic 296 
expansion with dysplasia by WHO criteria [61], [62] and for which no certain therapy has been 297 
established to date [63]. The association between ACAs typical of MDS, e.g. monosomy 7 and 298 
myelodysplasia is described above and in Tab.1. 299 
In our patient, MDS was initially classified as intermediate-1 by IPSS and high by WPSS. 300 
Clinical evidence for myelodysplasia was first noted 7.5 years after CML was diagnosed and 301 
5.5 years after detection of monosomy 7, which coincided with start TKI-therapy, illustrating 302 
the long latency period until the myelodysplasia became clinically apparent.  303 
 304 
 305 
Recurrent molecular aberrations  306 
During the course of the disease our patient developed 3 additional mutations: KRAS, ASXL1 307 
and ETV6. Backtracking by molecular analysis of cryopreserved probes demonstrated that 308 
these genomic aberrations had not been present when MDS was clinically first diagnosed (see 309 
Fig.2). KRAS belongs to the RAS superfamily of signaling proteins. Aberrant RAS function is 310 
associated with hyperproliferative developmental disorders and cancers [64], [65]. KRAS 311 
mutations occur with a frequency below 5% in different subtypes of MDS and its prognostic 312 
relevance remains uncertain [66]. In CML, RAS mutations are very rare and their precise role 313 
in disease development and prognostic relevance is controversial [64], [67], [68] although they 314 
have been associated with imatinib resistance in individual patients with CML [69]. ASXL1 is 315 
a histone modifying enzyme and therefore it is a part of the epigenetic regulatory machinery. 316 
Loss-of-function mutations of ASXL1 are found in 11-21% of MDS patients and in 10-15% of 317 
patients with myeloproliferative syndromes and are associated with a poor prognosis [70]–[73]. 318 
In CML, ASXL1 mutations have been reported in CP and BP and are relatively frequent [71]. 319 
It is not clear whether they are late or early events during disease development but they seem 320 
to contribute to disease progression [74]. ETV6 encodes a transcription factor and is frequently 321 
involved in translocations and deletions in hematologic malignancies [75]. ETV6-PDGFRB 322 
translocations for example have been described in AML secondary to MDS and in MDS 323 
patients with high risk features [76], [77]. A large study by Haferlach et al. revealed that ETV6 324 
rearrangements occur rarely in MDS (0,2%) [75], whereas data on ETV6 mutations in CML is 325 
extremely limited, with few case reports [78] and an apparent association with atypical BCR-326 
ABL1 negative CML [79]. Therefore it´s prognostic impact is unknown to date (see Tab.1). 327 
In our patient, the appearance of KRAS, ASXL1 and ETV6 mutations were markers of disease 328 
progression and considered to portend an unfavorable prognosis (see Fig.2), which in 329 
conjunction with appearance of myelodysplasia prompted addition of azacitidine. To date, no 330 
other data on prolonged combined treatment with TKI and a hypomethylating agent in the 331 
setting of CML chronic phase and myelodysplasia had been reported. 332 
Treatment options for TKI failure in CML  333 
The criteria for TKI failure are regularly updated and are described  in the  ELN guidelines [11]. 334 
They include a lack of hematologic, cytogenetic and molecular responses at specified 335 
timepoints (3, 6 and 12 months after TKI start). Therapeutic options include a switch to other 336 
2nd or 3rd generation TKIs considering kinase domain mutational status and risk of side effects, 337 
HSCT (extensively reviewed by [80]–[90]) or experimental treatment in a clinical trial [11]. 338 
Novel agents in current clinical testing include allosteric BCR/ABL inhibitors (ABL001) [91]–339 
[93], autophagy inhibitors (hydrochloroquine) [94]–[96], JAK2 inhibitors (Ruxolitinib) [97] and 340 
modulation of immune checkpoints by antibodies, e.g.  nivolumomab [98]–[103]. Notably, there 341 
are no reports to date on the outcome of transplantation in CML-associated myelodysplasia 342 
as described in this report.  343 
 344 
TKI treatment after allogeneic HSCT  345 
As HSCT is performed today mainly in high risk CML patients in case of TKI failure [80]–[90] 346 
a post-transplant TKI strategy becomes more and more important. Current recommendations 347 
suggest clearly a continuation of TKI treatment after HSCT if performed due to BC [104]. If 348 
HSCT was performed in AP or CP-CML there are in principle a preemptive and a MRD 349 
triggered approach like in Ph+ ALL [105]. To date there are no clear recommendations on that, 350 
but a strict MRD monitoring is essential after HSCT and in case of TKI treatment one has to 351 
consider the following caveats: Data is available mainly for Imatinib, but most patients who 352 
underwent transplant showed initial resistance to Imatinib and data about second and third 353 
generation TKIs are limited. If TKIs are administered prophylactically, TKI treatment can be 354 
started within the first month after HSCT and is in general well tolerated [106], although one 355 
hast to be aware of drug to drug interactions (immunsopressive treatemtn) and a potential 356 
weak haematopoesis. In case of relapse upon routine Bcr/Abl measurement, molecular, 357 
cytogenetic and haematologic relapse after HSCT can often successfully be treated with TKIs 358 
[107] and there is also an option in donor lymphocyte infusion in combination with TKI 359 
treatment [108]. 360 
Rationale for Azacitidine and TKI combination therapy 361 
Clinical experience with hypomethylating agents in CML is limited. High-dose decitabine was 362 
reported in a study with CML patients in accelerated or blast phase in the pre TKI era [109]. 363 
Decitabine at a dose of 750-1000 mg/m2 per course for 5 days was administered to 20 patients 364 
in blast phase and 17 patients in accelerated phase. Objective response rate was 25% and 365 
53% in blast phase and accelerated phase, respectively. Patients in blast phase reached CHR 366 
in 10%, pCyR in 5% and 15% had bone marrow CR without platelet recovery. Of the patients 367 
treated, 35% returned to second chronic phase (with 2 patients showing pCyR) and 18% 368 
showed hematologic improvement or partial hematologic response. Low-dose decitabine was 369 
administered to 5 CML patients at a dose of 15-20mg/m2 intravenously for a 10, 15 or 20 day 370 
cycle (1 chronic, 1 accelerated and 3 blast phase patients). 2 patients achieved a partial and 371 
2 a complete hematologic response [110]. The same group reported a phase II study of low-372 
dose decitabine in CML patients resistant to imatinib. 12 patients in chronic, 17 patients in 373 
accelerated and 6 patients in blast phase were treated with 10-15 mg/m2 for 10 days every 6 374 
weeks. A CHR was reached by 17-50%,e a pHR in 33-17%, a major CyR in 17-25% and a 375 
minor CyR in 17-33% of patients [111].  376 
Azacitidine treatment in combination with immunosuppressive drugs have been reported to be 377 
benefical in rare cases of MDS [112]. The combination of a hypomethylating agent and a TKI 378 
was tested in two interesting studies: in a phase II study combining low-dose decitabine (15 379 
mg/m2 for 5 days) with imatinib (600mg /day) in patients with accelerated (n=18) and blast 380 
phase (n=10), the CHR rate was 20% and 39%, respectively, and the major CyR rate 17% and 381 
20% [113]. In another study reported by Ghez et al., 5 patients in myeloid blast crisis were 382 
treated with the combination of 5-azacitidine for 7 days in 28 day cycles in combination with a 383 
second generation TKI. All patients achieved a CHR and two showed a CyR and a MMR after 384 
3-10 months of treatment [114]. The feasibility and efficacy of long term combination of a TKI 385 
for MDS secondary to CML has not yet been explored. 386 
Our patient had an indication for treatment with azacitidine on the basis of her worsening risk 387 
score (evolving to intermediate-2 after 6 months after diagnosis), with persistent grade 3-4 388 
neutropenia, transfusion dependency and increasing bone marrow fibrosis. Initially it was 389 
difficult to distinguish whether the dysplasia with cytopenia was therapy-associated or reflected 390 
progression of CML. Allogeneic HSCT was indicated based on the course of her CML but no 391 
matched sibling or unrelated donor was available, and no 3rd generation TKI was approved at 392 
that time. The decision for combining azacitidine and dasatinib was made in the face of the 393 
following caveats: lack of data on combined dasatinib and azacitidine, the risk of aggravating 394 
cytopenia and the potential for drug-drug interactions. The subsequent clinical course was 395 
characterized by sustained CCyR, but with persistence of detectable BCR-ABL1 transcripts. 396 
The MDS remained clinically and cytogenetically stable for 3 years, with appearance of a K-397 
Ras mutation as a possible negative prognostic factor for acceleration of MDS into AML [115], 398 
[116]. Despite these adverse genetic findings the patient´s clinical course remained stable for 399 
an additional several months with continued combination therapy. 400 
Our rationale for combining a TKI with a hypomethylating agent was supported by preclinical 401 
data: DNA methylation stimulates carcinogenesis by modification of DNA expression and 402 
consecutive silencing of tumor suppressors [117]. It has been shown that DNA methylation 403 
increases in progressive disease in CML [118] and furthermore that hypomethylating agents 404 
have single-agent activity in CML even in imatinib resistant cases [111], [119]. Moreover, 405 
synergistic effects of imatinib and decitabine had previously been shown in vitro in CML [120]. 406 
Accordingly, combined administration of hypomethylating agents and TKIs had the potential 407 
for enhanced and possibly synergistic activity compared with single agent treatment. 408 
 409 
Summary 410 
This case demonstrates an unusual course of CML, in which a variant translocation (t(9;22;17)) 411 
and an aberrant BCR-ABL transcript (e1a3) were detected at initial diagnosis, the latter being 412 
apparent not by routine RT-PCR but in nested PCR analysis. Primary treatment failure in 413 
response to imatinib according to ELN guidelines [11] prompted switching to Nilotinib but was 414 
complicated by acquisition of additional chromosomal abnormalities (monosomy 7) in a Ph 415 
negative clone. Nilotinib treatment resulted in a transient CCyR but no major molecular 416 
response (MMR). Cytogenetic relapse accompanied by pancytopenia posed a diagnostic 417 
challenge with a differential diagnosis of acceleration of the CML or emergence of b MDS. This 418 
cytogenetic relapse was treated with a switch to Dasatinib. Based on cytologic features during 419 
the further disease course, with pronounced dysplasia of the megakaryocyte and erythroid 420 
lineages, severe granulocytopenia but normal blast cell content, and cytogenetic detection of 421 
monosomy 7, a diagnosis of MDS was established. This prompted addition of azacitidine to 422 
dasatinib treatment, which was well tolerated and achieved prolonged clinical stabilization. 423 
Subsequent evidence of clonal evolution was development of a K-RAS mutation and loss of 424 
cytogenetic remission after 4 years under combination treatment. 425 
Haploidentical BMT was performed as potentially curative therapy, resulting in a sustained 426 
complete cytogenetic remission, full donor chimerism and undetectable BCR-ABL1 (checking 427 
for both typical and atypical transcripts) except for one intercurrent molecular relapse 2.5 years 428 
after transplant that was successfully treated with Nilotinib and two further detections revealing 429 
low level atypical BCR-ABL1 transcripts on day +1036 and day +1477 disappearing without 430 
tretament. 431 
This case exemplifies the feasibility of long-term combined therapy with a hypomethylating 432 
agent and a TKI in patients with CML coincident with MDS, but also highlights the continued 433 
importance of allogeneic HSCT, including alternative donor transplant, as a definite curative 434 
treatment option. The pivotal role of appropriate molecular monitoring, including of atypical 435 
BCR-ABL1 transcripts and awareness of additional aberrations unrelated to CML but 436 
diagnostic of a second hematologic malignancy such as MDS is also emphasized. 437 
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Figure legends 465 
Table 1: Uncommon prognostic features of CML represented in this case 466 
Prognostically relevant features illustrated in this case are generally of low frequency (except 467 
of ASXL1 mutation). Nevertheless, their influence on overall prognosis, while variable ranging 468 
from worsening prognosis to an uncertain role, have to be considered and should prompt 469 
rigorous BCR-ABL monitoring even when this is technically difficult such as in case of atypical 470 
transcripts. 471 
 472 
 473 
Table 2: Results of cytogenetic analysis 474 
The results of the continuous cytogenetic analysis are shown and illustrate clonal evolution 475 
and development of additional chromosomal aberrations and monosomy 7 under different 476 
subsequent therapies in this case including azacitidine and dasatinib combination. The 477 
numbers of detected cytogenetic abnormal cells are indicated in [/]. 478 
 479 
Figure 1A-C Blood count:  480 
A Haemoglobin levels 481 
The haemoglobin levels over time represent the course of the disease showing a transfusion 482 
independent anemia (grade 1-2). Hb levels are presented in g/dl. 483 
B Thrombocyte count 484 
Thrombocyte count also over time reflects disease progression with mild thrombocytopenia 485 
(grade 1-2), not resulting in any bleeding complications. Thrombocyte counts are shown in 486 
thrombocytes /nl. 487 
C Absolute neutrophil count 488 
The absolute neutrophil count is the most sensitive parameter in the course of the disease of 489 
this patient. The progression results in a severe grade 4 (severe) granulocytopenia requiring 490 
antibiotic prophylaxis. ANC is shown in neutrophils /nl. Severe granulocytopenia did not 491 
change under dasatinib / azacitidine treatment. 492 
 493 
Figure 2: Disease and treatment history 494 
The emergence of different clones and molecular aberrations correlates with the development 495 
of MDS and the loss of cytogenetic response. Notably, appearance of monosomy 7 predates 496 
manifestation of MDS by 2 years. The corresponding therapeutic regimens are shown, 497 
demonstrating prolonged disease stabilization by combined dasatinib and azacitidine 498 
treatment for 4 years. The atypical BCR-ABL transcript was detectable continuously prior to 499 
SCT. Worsening of red blood count (RBC) and platelet count (Plts) are indicated by * and # 500 
respectively. 501 
 502 
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Table 1: uncommon prognostic aspects of CML in this case 1003 
Feature Frequency 
 
Prognostic role in CML 
 
Caveats References 
Variant BCR-ABL 
translocations 
6% 
Inferior in pre TKI era / 
unclear in TKI era 
Speculated to be a marker of genomic instability  
 
[2], [17]–[21] 
Atypical BCR-ABL 
transcripts 
sporadically Uncertain BCR/ABL monitoring difficult [24]–[31] 
Additional 
chromosomal 
aberrations (ACAs) 
In Ph positive clones 
5% 
(more common 
in AP and blast 
phase: 30-80%) 
Negative predictor if present 
at initial diagnosis 
Prognostic role unclear if developed under TKI, but 
considered as warning sing 
[11], [37]–[42] 
 
ACA in independent 
Ph negative clones 
rare uncertain Possibly TKI therapy induced 
[43], [48], 
[49], [52] 
 
Myelodysplasia in CML 
 
rare 
If associated with monosomy 
7 poor 
TKI side effects or MDS/MPN overlap syndrome [15], [53]–[56] 
KRAS mutation very rare  Controversial prognostic role association with Imatinib resistance reported [64]–[69] 
ASXL1 mutation frequent 
May contribute to disease 
progression 
Poor prognosis in MDS and MPNs [70]–[73] 
ETV6 mutation occasional no data  occurs in high risk MDS [75]–[78] 
 1004 
 1005 
 1006 
 1007 
 
Table 2: Results of cytogenetic analysis  1008 
    (Note: in all cases a female karyotype 45 XX was detected additionally) 1009 
1010 
Date   Results 
 
Therapy 
 
Response 
17.02.2001 t(9:22:17) [9/9] Litalir Primary diagnosis 
09.09.2004 No viable cells Imatinib n.a. 
16.03.2006 t(9:22) [19/25] Nilotinib Partial cytogenetic remission (pCyR) 
09.08.2006 t(9:22:17) [4/20], -7 [16/20] Nilotinib pCyR 
24.11.2006 t(9:22:17) [6/20], -7 [14/20] Nilotinib pCyR 
06.02.2007 t(9:22:17) [2/21], -7 [19/21] Nilotinib pCyR 
22.05.2007 -7 [19/19] Nilotinib First  complete cytogenetic remission (cCyR) 
04.09.2007 -7 [20/20]  Nilotinib cCyR 
08.01.2008 -7 [21/21]  Nilotinib cCyR 
30.04.2008 t(9:22:17) [3/21], -7 [18/21]  Dasatinib First cytogenetic relapse 
20.08.2008 -7 [20/20]  Dasatinib Second complete cytogenetic remission (cCyR) 
08.12.2008 -7 [14/16]  Dasatinib cCyR 
15.12.2009 -7 [2/2]  Dasatinib + Azacitidine cCyR 
15.10.2010 -7 [20/20]  Dasatinib + Azacitidine cCyR 
03.05.2011 
-7 [13/21], -7 der(22)t(2;22) [6/21], 
t(9;22;17) [2/21]  
Dasatinib + Azacitidine Second cytogenetic relapse 
 
  1011 
 1012 
 1013 
 1014 
 1015 
 1016 
 1017 
 1018 
 1019 
 1020 
 1021 
 1022 
 1023 
 1024 
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 1027 
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 1029 
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Figure 1: Blood count 
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Figure 2: Disease and treatment history 
 
